2 completed, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow John Hays: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy Nivolumab - Colon Adenoma, Colon Carcinoma | Phase 2 | Terminated | John Hays | 3 | 2018-10-04 | 2024-07-01 |
| Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab panitumumab, irinotecan hydrochloride, fluorouracil - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Completed | John Hays | 16 | 2013-02-01 | 2025-02-05 |
| Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer aflibercept, oxaliplatin, leucovorin - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Completed | John Hays | 56 | 2012-11-14 | 2025-02-05 |
Colonic Neoplasms (3) · Rectal Neoplasms (2) · Colorectal Neoplasms (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1)
Fluorouracil (2) · Leucovorin (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Fluorodeoxyglucose F18 (1) · Irinotecan (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Oxaliplatin (1) · Panitumumab (1) · aflibercept (1)
United States (3)